drugset / Trial / NCT00491569
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
Phase 2
Completed
60 enrolled
China Medical University Hospital
National Health Research Institutes, Taiwan · collabNational Science and Technology Council, Taiwan · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients. The purpose of this study is to compare efficacy and safety of add-on treatment of sarcosine, a GlyT-1 inhibitor, and D-serine, an NMDA-glycine site agonist, in chronically stable schizophrenia patients who have been stabilized with antipsychotics.
Timeline
- Start
- 2005-01
- Primary completion
- —
- Completion
- 2006-12
Publications
- Background Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005 Nov;62(11):1196-204. doi: 10.1001/archpsyc.62.11.1196.
- Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010 May;13(4):451-60. doi: 10.1017/S1461145709990939. Epub 2009 Nov 4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D-serine | Unknown | 2 g | — |
| Subject | Sarcosine | Other / unclassified | 2 g | — |